In Vivo Calpain/Caspase Cross-talk during 3-Nitropropionic Acid-induced Striatal Degeneration

The role of caspases and calpains in neurodegeneration remains unclear. In this study, we focused on these proteases in a rat model of Huntington's disease using the mitochondrial toxin 3-nitropropionic acid (3NP). Results showed that 3NP-induced death of striatal neurons was preceded by cytochrome c redistribution, transient caspase-9 processing, and activation of calpain, whereas levels of the active/processed form of caspase-3 remained low and were even reduced as compared with control animals. We evidenced here that this decrease in active caspase-3 levels could be attributed to calpain activation. Several observations supported this conclusion. 1) Pharmacological blockade of calpain in 3NP-treated rats increased the levels of endogenous processed caspase-9 and caspase-3. 2) Cell-free extracts prepared from the striatum of 3NP-treated rats degraded in vitro the p34 and p20 subunits of active recombinant caspase-9 and caspase-3, respectively. 3) This degradation of p34 and p20 could be mimicked by purified μ-calpain and was prevented by calpain inhibitors. 4) μ-Calpain produced a loss of the DEVDase (Asp-Glu-Val-Asp) activity of active caspase-3. 5) Western blot analysis and experiments with 35S-radiolabeled caspase-3 showed that μ-calpain cleaved the p20 subunit of active caspase-3 near its catalytic site. 6) μ-Calpain activity was selectively inhibited (IC50 of 100 μm) by a 12 amino acid peptide corresponding to the C terminus of p20. Our results showed that calpain can down-regulate the caspase-9/caspase-3 cell death pathway during neurodegeneration due to chronic mitochondrial defects in vivo and that this effect may involve, at least in part, direct cleavage of the caspase-3 p20 subunit.

[1]  Emmanuel Brouillet,et al.  The Mitochondrial Toxin 3-Nitropropionic Acid Induces Striatal Neurodegeneration via a c-Jun N-Terminal Kinase/c-Jun Module , 2002, The Journal of Neuroscience.

[2]  S. Harwood,et al.  Calpain inhibitor I reduces the activation of nuclear factor-k B and organ injury / dysfunction in hemorrhagic shock , 2000 .

[3]  Joseph B. Martin Huntington's disease , 1984, Neurology.

[4]  Changlian Zhu,et al.  Synergistic Activation of Caspase-3 by m-Calpain after Neonatal Hypoxia-Ischemia , 2001, The Journal of Biological Chemistry.

[5]  Marian DiFiglia,et al.  Excitotoxic injury of the neostriatum: a model for Huntington's disease , 1990, Trends in Neurosciences.

[6]  Peng Li,et al.  Direct Cleavage by the Calcium-activated Protease Calpain Can Lead to Inactivation of Caspases* , 2000, The Journal of Biological Chemistry.

[7]  James R. Burke,et al.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.

[8]  C. Guégan,et al.  Specific Caspase Pathways Are Activated in the Two Stages of Cerebral Infarction , 2001, The Journal of Neuroscience.

[9]  Françoise Condé,et al.  Replicating Huntington's disease phenotype in experimental animals , 1999, Progress in Neurobiology.

[10]  G. Cole,et al.  Activation of Calpain I Converts Excitotoxic Neuron Death into a Caspase-independent Cell Death* , 2000, The Journal of Biological Chemistry.

[11]  M. Beal,et al.  Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.

[12]  B R Rosen,et al.  1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.

[13]  S. Krajewski,et al.  Calpain Is a Major Cell Death Effector in Selective Striatal Degeneration Induced In Vivo by 3-Nitropropionate: Implications for Huntington's Disease , 2003, The Journal of Neuroscience.

[14]  C. Cepeda,et al.  Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease , 2001, The Journal of Neuroscience.

[15]  F. Condé,et al.  Partial Inhibition of Brain Succinate Dehydrogenase by 3‐Nitropropionic Acid Is Sufficient to Initiate Striatal Degeneration in Rat , 1998, Journal of neurochemistry.

[16]  J. Cooper,et al.  Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.

[17]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[18]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[19]  B. Rosen,et al.  Age‐Dependent Vulnerability of the Striatum to the Mitochondrial Toxin 3‐Nitropropionic Acid , 1993, Journal of neurochemistry.

[20]  L. Ellerby,et al.  Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Snyder,et al.  Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization , 1999, Nature Medicine.

[22]  D. Green,et al.  Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. , 1999, Blood.

[23]  Z. Qin,et al.  Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Dash,et al.  Caspase activity plays an essential role in long‐term memory , 2000, Neuroreport.

[25]  R. Albin,et al.  Alternative excitotoxic hypotheses , 1992, Neurology.

[26]  M. Beal,et al.  Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.

[27]  M. DiFiglia,et al.  Pro-caspase-8 Is Predominantly Localized in Mitochondria and Released into Cytoplasm upon Apoptotic Stimulation* , 2001, The Journal of Biological Chemistry.

[28]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[29]  N. Thornberry,et al.  The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis , 1996, Nature Structural Biology.

[30]  B. Hyman,et al.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[31]  Elsdon Storey,et al.  Excitotoxin Lesions in Primates as a Model for Huntington's Disease: Histopathologic and Neurochemical Characterization , 1993, Experimental Neurology.

[32]  Kevin K. W Wang,et al.  Calpain and caspase: can you tell the difference? , 2000, Trends in Neurosciences.

[33]  M. Beal,et al.  Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.

[34]  L. Raymond,et al.  Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.